ArticleDigital biomarkers
Actigraphy-Quantified Physical Activity Measurements in Patients with Symptomatic
Article in Digital biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03439514 (A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Who cites it
1 citing paper in PubMed.
- Evaluation of Inter-Method Reliability Between Palarum PUP Smart SocksSensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Actigraphy-quantified physical activity (PA) allows for continuous measurements of PA that are reflective of real-world day-to-day functioning and morbidity in persons living with cardiomyopathy. This analysis reports the results of actigraphy monitoring and relates these to other clinical outcome assessments in the phase 3, multinational REALM-dilated cardiomyopathy (DCM) (NCT03439514) clinical trial in Methods: Between 2020 and 2022, REALM-DCM randomized 37 patients with actigraphy worn on the nondominant wrist continuously to monitor daily PA. Of those, 35 participants had analyzable data for this analysis. Results: The median duration of actigraphy monitoring for all participants was 293 days across 120 patient visits. Over 85% of the visits met a predefined threshold of wear-time compliance of 10 h of awake wear time for at least 4 days within the 2-week monitoring period prior to and after clinic visits. Kansas City Cardiomyopathy Questionnaire (KCCQ) physical limitation scores were positively associated with several actigraphy-quantified PA metrics, including moderate-to-vigorous physical activity (MVPA), moderate activity, non-sedentary behavior, total step counts, total activity counts (all 3 axes and their vector magnitude). Six-minute walk time distance was positively associated with time spent in MVPA and moderate activity, and total step counts. Patient Global Impression (PGI) Symptom Heart Failure Severity was negatively associated with non-sedentary behavior, total activity counts (vector magnitude, X- and Y-axes), and light activity. Actigraphy endpoints also distinguished between NYHA class II and class III patients. Actigraphy endpoints did not correlate with the KCCQ total score. Conclusion: This is the largest and most longitudinal dataset of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.